---
title: "Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Tuesday When Compared To Competitors"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274722411.md"
description: "Corbus Pharmaceuticals Holdings Inc. (CRBP) shares fell 2.17% to $8.10 on Tuesday, underperforming against competitors amid a declining stock market. The NASDAQ Composite Index dropped 1.43%, while the Dow Jones Industrial Average fell 0.34%. Corbus is currently 60.60% below its 52-week high of $20.56. In contrast, Vanda Pharmaceuticals Inc. rose 4.01%, while Fortress Biotech Inc. and Viking Therapeutics Inc. saw minor declines. Trading volume was significantly below the 50-day average."
datetime: "2026-02-03T22:23:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274722411.md)
  - [en](https://longbridge.com/en/news/274722411.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274722411.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/274722411.md) | [繁體中文](https://longbridge.com/zh-HK/news/274722411.md)


# Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Tuesday When Compared To Competitors

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Corbus Pharmaceuticals Holdings Inc. (CRBP) slid 2.17% to $8.10 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index falling 1.43% to 23,255.19 and Dow Jones Industrial Average falling 0.34% to 49,240.99.

Corbus Pharmaceuticals Holdings Inc. closed 60.60% short of its 52-week high of $20.56, which the company reached on October 20th.

The stock underperformed when compared to some of its competitors Tuesday, as Vanda Pharmaceuticals Inc. (VNDA) rose 4.01% to $8.05, Fortress Biotech Inc. (FBIO) fell 1.90% to $3.09, and Viking Therapeutics Inc. (VKTX) fell 1.70% to $29.41.

Trading volume (102,539) remained 212,405 below its 50-day average volume of 314,944.

Data source: Dow Jones Market Data, FactSet. Data compiled February 3, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

02-03-26 1723ET

### Related Stocks

- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [Vanda Pharmaceuticals Inc. (VNDA.US)](https://longbridge.com/en/quote/VNDA.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [Corbus Pharmaceuticals Holdings, Inc. (CRBP.US)](https://longbridge.com/en/quote/CRBP.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)

## Related News & Research

- [Xeris Biopharma Q4 product revenue beats analyst expectations, driven by higher patient demand](https://longbridge.com/en/news/277460502.md)
- [TD Asset Management Inc Increases Position in Nuvalent, Inc. $NUVL](https://longbridge.com/en/news/277627358.md)
- [BUZZ-MAIA Biotechnology plunges after $30 million share sale](https://longbridge.com/en/news/277605454.md)
- [FDA approves Ascendis Pharma’s weekly Yuviwel for paediatric dwarfism](https://longbridge.com/en/news/277455732.md)
- [Argenx Unveils New VYVGART and Neurology Pipeline Data Ahead of 2026 AAN Meeting](https://longbridge.com/en/news/278091205.md)